Jump to content

Recommended Posts

Posted

PARIS, Sep. 4, 2007 -- Pharmaceutical company Sanofi-Aventis said seven trials of its Taxotere drug in treating non-small cell lung cancer showed a 'significant' improvement in overall survival rates versus existing treatments.

Taxotere, an anti-cancer agent used in other treatments, is the company's fourth best-selling drug.

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.